Literature DB >> 7193688

Inheritance of the human platelet alloantigen, PlA1, in type I Glanzmann's thrombasthenia.

T J Kunicki, D Pidard, J P Cazenave, A T Nurden, J P Caen.   

Abstract

The hereditary of the human platelet alloantigen, PlA1, has been studied in Glanzmann's thrombasthenia. The PlA1 content of platelets from three patients, 20 kindred of these patients, including parents and siblings, and 15 unrelated normal individuals was determined using immunologic techniques based on the release of 51Cr from labeled platelets. The amount of membrane glycoproteins (GP) IIb and IIIa in the platelets of these individuals was determined by quantitative crossed immunoelectrophoresis of Triton X-100 soluble proteins using a multispecific rabbit antibody raised against normal platelets. Platelets from the three thrombasthenic patients contained neither detectable GP IIb and GP IIIa nor detectable PlA1 antigen. Platelets from seven kindred with normal amounts of GP IIb and GP IIIa contained PlA1 antigen levels identical to those detected in platelets of normal individuals. Platelets from 13 kindred, including each parent studied, were shown to contain an amount of GP IIb and GP IIIa equivalent to 53% of that amount detected on normal platelets. Platelets from the same individuals expressed amounts of PlA1 antigen that were either 54.0 +/- 4.1 (mean +/- SD) or 28.0 +/- 2.7% of that present on platelets of normal individuals homozygous for the Al allele. The results presented in this report provide evidence that the expression of the thrombasthenic glycoprotein abnormality and the inheritance of PlA1 antigen are controlled by different genes. These results further suggest that lack of expression of the PlA1 antigen on thrombasthenic platelets results from the decrease or absence of the glycoprotein carrier of the PlA1 determinant, previously shown to be GP IIIa.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7193688      PMCID: PMC370622          DOI: 10.1172/JCI110088

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Serological and genetical studies on a platelet antigen (Zw).

Authors:  J VAN LOGHEM JJ; H DORFMEIJER; M VAN HART; F SCHREUDER
Journal:  Vox Sang       Date:  1959-04       Impact factor: 2.144

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

4.  Further studies on the protein composition and surface structure of normal platelets and platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome.

Authors:  I Hagen; N O Solum
Journal:  Thromb Res       Date:  1978-11       Impact factor: 3.944

5.  Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis.

Authors:  D R Phillips; P P Agin
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

6.  [Glanzmann thrombasthenia, PLA1 antigen and anti-Glanzmann antibody].

Authors:  J Y Muller; C Patereau; J P Soulier
Journal:  Rev Fr Transfus Immunohematol       Date:  1978-12

7.  Immunization, isolation of immunoglobulins, estimation of antibody titre.

Authors:  N Harboe; A Ingild
Journal:  Scand J Immunol Suppl       Date:  1973

8.  Effects of cephalothin and penicillin G on platelet function in vitro.

Authors:  M A Guccione; M A Packham; J F Mustard
Journal:  Br J Haematol       Date:  1977-01       Impact factor: 6.998

9.  Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome.

Authors:  I Hagen; A Nurden; O J Bjerrum; N O Solum; J Caen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

10.  Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins.

Authors:  D R Phillips; P P Agin
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

View more
  4 in total

1.  Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families.

Authors:  Mathieu Fiore; Xavier Pillois; Paquita Nurden; Alan T Nurden; Frédéric Austerlitz
Journal:  Eur J Hum Genet       Date:  2011-04-13       Impact factor: 4.246

2.  A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane.

Authors:  A T Nurden; J P Rosa; D Fournier; C Legrand; D Didry; A Parquet; D Pidard
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

3.  Surface modifications in the platelets of a patient with alpha-N-acetyl-D-galactosamine residues, the Tn-syndrome.

Authors:  A T Nurden; D Dupuis; D Pidard; N Kieffer; T J Kunicki; J P Cartron
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

4.  Absence of platelet membrane glycoproteins IIb/IIIa from monocytes.

Authors:  K J Clemetson; J L McGregor; R P McEver; Y V Jacques; D F Bainton; W Domzig; M Baggiolini
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.